Albumin Interferon   ANA773 and ANA598   BI 201335   Boceprevir (aka SCH 503034)   GS 9132, GS 9190 and GS 9450   IDX136, IDX316, IDX375 and IDX184   IMO-2125   MK-0608 and MK-7009   Narlaprevir   Nitazoxanide	Pegylated Interferon Lambda   PSI-879, PSI-7851 and PSI-7977   RG7227, RG7128 and R1626   Sorafenib (Nexavar)   Telaprevir (aka VX-950)   TMC435   VCH-759, VCH-916 and VCH-222   Viramidine (aka Taribavirin)

Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010

IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study
5/01/09

Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees
5/01/09

Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor
4/24/09

Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors
4/24/09

Toll-like Receptor Antagonist IMO-2125 Stimulates Production of Natural Interferons with Activity against Hepatitis C Virus
12/13/09

Idera Pharmaceuticals Begins Phase 1 Trial of Toll-like Receptor Agonist IMO-2125 for Chronic Hepatitis C
10/13/09

Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09

MK-7009 Significantly Improves Rapid Viral Response (RVR) in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C (CHC) Genotype 1 Infection
4/24/09

Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
11/03/09

Pharmasset Starts Trial of HCV Polymerase Inhibitor PSI-7977 for Genotype 1 Chronic Hepatitis C Patients
1/29/2010

Pharmasset Selects Investigational HCV Polymerase Inhibitor PSI-879 for Preclinical Development
10/09/09

Pharmasset Initiates First Clinical Trial of Second-generation HCV Polymerase Inhibitor PSI-7851
4/10/09

Albumin Interferon (Albuferon) and HCV Polymerase Inhibitor PSI-7851 Advance in Clinical Trials
7/31/09

Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010

Pharmasset Announces Continuation of Phase 2b Trial of HCV Polymerase Inhibitor RG7128
12/04/09

Oral HCV Polymerase Inhibitor RG7128 plus Protease Inhibitor RG7227 (ITMN-191) Suppresses HCV Viral Load without Interferon or Ribavirin
11/13/09

InterMune and Roche Begins Trial of Ritonavir-boosted ITMN-191 (RG7227) for Genotype 1 Chronic Hepatitis C Patients
10/06/09

Roche and InterMune Begin Phase 2b Trial of HCV Protease Inhibitor RG7227/ITMN-191
9/04/09

Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09

New Hepatitis C Treatment Trials: HCV Polymerase Inhibitor R7128, Nucleotide Prodrug IDX184, and Albumin Interferon (Albuferon)
1/20/09

HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
11/14/08

R7128 plus ITMN-191 Perform Well in Laboratory Study; STAT-C Combination Clinical Trial Now Underway
11/14/08

Natural Prevalence of Resistance to HCV Protease Inhibitors
9/25/08

Combination Therapy with Investigational HCV Polymerase Inhibitor R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV
9/12/08

Pharmasset Releases Preliminary Data from Phase 1 Study of Investigational HCV Polymerase Inhibitor R7128
8/08/08

InterMune and Anadys Begin Phase 1 Clinical Trials of Experimental HCV Therapies ITMN-191 and ANA598
6/06/08

R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded
4/29/08

HCV Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance
4/29/08

InterMune Presents Top-line Results from Phase 1b Trial of HCV Protease Inhibitor ITMN-191 Monotherap
4/04/08

Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/10

HCV Protease Inhibitor Telaprevir Demonstrates Good Efficacy in Both Treatment-experienced and Treatment-naive Patients
11/10/09

Vertex Aims to Receive $250 Million in Milestone Payments for Anti-HCV Drug Telaprevir after Approval in Europe
7/14/09

Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/01/09

HCV Protease Inhibitor Telaprevir (VX-950) Continues to Perform Well in PROVE Trials
11/11/08

Tibotec Begins Enrolling Phase III Study of HCV Protease Inhibitor Telaprevir for Hepatitis C Patients with Prior Treatment Failure
10/24/08

Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study
7/22/08

Vertex Reports Encouraging Data from PROVE3 Trial of HCV Protease Inhibitor Telaprevir (VX-950)
6/13/08

Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV
4/26/08

Vertex and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis C Patients
3/21/08

Vertex to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir (VX-950)
2/01/08

Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09

OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype-1 HCV patients
5/01/09

Antiviral activity and safety of TMC435 combined with peginterferon -2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy
5/01/09

Experimental HCV Protease Inhibitor TMC435350 Demonstrates Favorable Safety and Efficacy in Phase 2a Trial
11/11/08

Experimental HCV Protease Inhibitor TMC435350 Demonstrates Promising Activity and Tolerability in Early Clinical Trial
5/13/08

Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09

Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
3/15/09

Naturally Occurring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-naive Hepatitis C Patients
1/09/09

Natural Prevalence of Resistance to HCV Protease Inhibitors
9/25/08

Vertex, InterMune, and Idenix Present Hepatitis C Drug Development Updates at Investor Conference
1/22/2010

Viramidine Fails to Show Non-inferiority to Ribavirin at Tested Doses, but Causes Less Anemia
1/19/2010

Prodrug Taribavirin Produces Equivalent Response, but Less Anemia than Ribavirin at 48 Weeks
12/02/08

Taribavirin Efficacy Similar to Ribavirin in Combination Therapy for Hepatitis C, but with Less Anemia
5/09/08

Valeant Reports Promising 12-week Phase IIb Data on Taribavirin
4/01/08